title: Prestroke glycemic control is associated with the functional outcome in acute ischemic stroke: the Fukuoka Stroke Registry.
abstract: OBJECTIVE
  Diabetes mellitus is an established risk factor for stroke. However, it is uncertain whether prestroke glycemic control (PSGC) status affects clinical outcomes of acute ischemic stroke. The aim of this study was to elucidate the association between PSGC status and neurological or functional outcomes in patients with acute ischemic stroke.
  
  
  METHODS
  From the Fukuoka Stroke Registry (FSR), a multicenter stroke registry in Japan, 3627 patients with first-ever ischemic stroke within 24 hours after onset were included in the present analysis. The patients were categorized into 4 groups based on their PSGC status: excellent (hemoglobin [Hb] A1c on admission<6.2%), good (6.2-6.8%), fair (6.9-8.3%) and poor (≥8.4%). Study outcomes were neurological improvement (≥4 points decrease in the National Institutes of Health Stroke Scale [NIHSS] score during hospitalization or 0 points on NIHSS score at discharge), neurological deterioration (≥1 point increase in NIHSS score) and poor functional outcome (death or dependency at discharge, modified Rankin Scale 2-6).
  
  
  RESULTS
  The age- and sex-adjusted ORs for neurological improvement were lower, and those for neurological deterioration and a poor functional outcome were higher in patients with poorer PSGC status. After adjusting for multiple confounding factors, these trends were unchanged (all probability values for trends were <0.002). These findings were comparable in patients with noncardioembolic and cardioembolic infarctions.
  
  
  CONCLUSIONS
  In ischemic stroke patients, HbA1c on admission was an independent significant predictor for neurological and functional outcomes.
authors.affiliation: Department of Nephrology, Hypertension, and Strokology, Graduate School of Medical Sciences, Kyushu University, Maidashi 3-1-1, Higashi-ku, Fukuoka 812-8582, Japan. kamouchi@intmed2.med.kyushu-u.ac.jp
authors.forename: Masahiro
authors.initials: M
authors.lastname: Kamouchi
authors.forename: Takayuki
authors.initials: T
authors.lastname: Matsuki
authors.forename: Jun
authors.initials: J
authors.lastname: Hata
authors.forename: Takahiro
authors.initials: T
authors.lastname: Kuwashiro
authors.forename: Tetsuro
authors.initials: T
authors.lastname: Ago
authors.forename: Yoshiki
authors.initials: Y
authors.lastname: Sambongi
authors.forename: Yoshihisa
authors.initials: Y
authors.lastname: Fukushima
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Sugimori
authors.forename: Takanari
authors.initials: T
authors.lastname: Kitazono
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D001786:Blood Glucose; D002545:Brain Ischemia / Q000150:complications / Q000175:diagnosis* / Q000503:physiopathology; D003920:Diabetes Mellitus / Q000188:drug therapy* / Q000503:physiopathology; D005260:Female; D006801:Humans; D006943:Hyperglycemia / Q000188:drug therapy* / Q000503:physiopathology; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D007564:Japan; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012042:Registries; D012307:Risk Factors; D012720:Severity of Illness Index; D020521:Stroke / Q000150:complications / Q000175:diagnosis* / Q000503:physiopathology; D016896:Treatment Outcome
chemical_list: D001786:Blood Glucose; D007004:Hypoglycemic Agents